VUB spin-off Camel-IDS collects 37m euros
Camel-IDS, a spin-off company of the VUB developing cancer-targeted radiopharmaceuticals, secured EUR 37m in a Series A investment round led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel) and BioMedPartners (Switzerland). Existing investors also participated. The previous capital increase, led by business angels and with the support of the Brussels Region and Innoviris, has enabled Camel-IDS to generate results that made it possible to secure the next development cycle.
The proceeds will enable Camel-IDS to run a phase Ib/II trial with its lead program CAM-H2 targeting HER2-positive brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline.
"Brain metastases in breast cancer are devastating for
patients and difficult to treat. The lead program at Camel-IDS is focused on
the development of a new treatment option for this condition. We are heartened
by the strong interest of the investors that will enable us to bring this
treatment to the patients."
- Tony Lahoutte, CSO and co-founder
Camel-IDS originated in 2015 from the Molecular Image Processing research group and the Department of Nuclear Medicine at UZ Brussel led by Prof. dr. Tony Lahoutte. Other researchers who contributed to the success of this spin-off are Geert Raes, Matthias D'Huyvetter, Nick Devoogdt and Jens De Vos.
Watch a video by Kanaal Z about the spin-off and its technology.